Clinical Trial Update: REPEAT Study - Resistance to ErythroPoietin Effectiveness Algorithm Trial [Phase 3]

View source ↗

Summary

The REPEAT Study, a Phase 3 trial evaluating a resistance-to-erythropoietin effectiveness algorithm in chronic kidney disease, has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• Erythropoietin (erythropoietin)

Snippet

Sponsor: Queen's University | Conditions: Kidney Failure, Chronic, Drug Resistance | Phase 3 | Status: TERMINATED